Akebia Therapeutics (AKBA) Cash from Operations Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -84.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.22% |
| Mar 31, 2026 | -56.08% |
| Dec 31, 2025 | 797.02% |
| Sep 30, 2025 | 519.79% |
| Jun 30, 2025 | 321.98% |
| Mar 31, 2025 | 30.08% |
| Dec 31, 2024 | -93.50% |
| Sep 30, 2024 | 6.59% |
| Jun 30, 2024 | -377.38% |
| Mar 31, 2024 | -10.80% |
| Dec 31, 2023 | 95.78% |
| Sep 30, 2023 | -121.20% |
| Jun 30, 2023 | 111.84% |
| Mar 31, 2023 | 18.88% |
| Dec 31, 2022 | 12.94% |
| Sep 30, 2022 | 160.08% |
| Jun 30, 2022 | 51.44% |
| Mar 31, 2022 | 69.44% |
| Dec 31, 2021 | -104.04% |
| Sep 30, 2021 | -106.59% |